# Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

Study · id `cardio:ct-nct05749874` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05749874](<https://clinicaltrials.gov/study/NCT05749874>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05749874

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2024 participants.

## Technical summary

Registry record NCT05749874. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-31 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2024 participants (enrolled count; ClinicalTrials.gov record NCT05749874, source copy `cardio:ctgov-nct05749874-2025-12-31`, retrieved 2026-10-26)
- Started: 2023-10-31 (actual) (ClinicalTrials.gov record NCT05749874, source copy `cardio:ctgov-nct05749874-2025-12-31`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05749874, source copy `cardio:ctgov-nct05749874-2025-12-31`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05749874, source copy `cardio:ctgov-nct05749874-2025-12-31`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05749874, source copy `cardio:ctgov-nct05749874-2025-12-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05749874-2025-12-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
- Acronym: ABCD
- Condition: PreDiabetes
- Condition: Abdominal Obesity
- Condition: Hypertension
- Condition: Dyslipidemias
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Berberine plus lifestyle intervention
- Intervention (Behavioral): Placebo plus lifestyle intervention
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 59b40460e5934b1801077d25d5b550768e9052b4ae1851f9b4c7d02c92b88ca3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
